Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00615212 · ClinicalTrials.gov registry record · Phase 1
Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00615212 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 23 participants.
The verdict
NCT00615212, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is meant to assess potential inhibitory effects of GSK376501 on CYP450 isoenzymes 3A4, 2C8, 2C9. subjects will receive probe compounds and systemic levels of these substrates will be compared pre and post dosing of GSK376501.
Interventions
- DRUG Midazolam
- DRUG Rosiglitazone
- DRUG Flurbiprofen
- DRUG GSK376501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-01-02 |
| Est. Completion | 2008-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00615212
The ClinicalTrials.gov registry entry for NCT00615212 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Midazolam is the first listed.
NCT00615212 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00615212 about?
NCT00615212 is a clinical study titled "Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects". This study is meant to assess potential inhibitory effects of GSK376501 on CYP450 isoenzymes 3A4, 2C8, 2C9. subjects will receive probe compounds and systemic levels of these substrates will be compared pre and post dosing of GSK376501.
What is the current status of trial NCT00615212?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2008-01-02. Estimated completion is 2008-02-15.
What interventions are being tested in trial NCT00615212?
The interventions under investigation include: Midazolam (DRUG), Rosiglitazone (DRUG), Flurbiprofen (DRUG), GSK376501 (DRUG).
Who is sponsoring clinical trial NCT00615212?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.